Soleus Capital Management’s DA32 Life Science Tech Acquisition Corp. Class A Common Stock DALS Stock Holding History

Soleus Capital Management’s Portfolio DALS Stock Details DALS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-50,000	Closed	-$487K	–	95
2022 Q3	$487K	Hold	50,000	–	–	0.07%	73
2022 Q2	$485K	Sell	50,000 -50,000	-50%	-$486K	0.08%	72
2022 Q1	$972K	Sell	100,000 -250,000	-71%	-$2.41M	0.13%	63
2021 Q4	$3.43M	Hold	350,000	–	–	0.34%	47
2021 Q3	$3.44M	Buy	+350,000	New	+$3.46M	0.54%	44

Other funds holding DALS

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

CIM

Cowen Investment Management New York $12M AUM 1.47% 1-Year Est. Return

Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return

MCM

Moore Capital Management New York $4.92B AUM 35.41% 1-Year Est. Return

Soleus Capital Management's DALS Position: Q4 2022 in Review

Soleus Capital Management sold out of DA32 Life Science Tech Acquisition Corp. Class A Common Stock (DALS) in Q4 2022, closing a stake of 50,000 shares — an estimated $487K sold.

Soleus Capital Management first reported a position in DALS in Q3 2021 and held it in 5 quarters. The position peaked at $3.44M in Q3 2021. 47 funds tracked by Wall St. Rank hold DALS as of Q4 2022.

Soleus Capital Management reported no remaining DA32 Life Science Tech Acquisition Corp. Class A Common Stock position as of Q4 2022 after selling out during the quarter.
Soleus Capital Management sold 50,000 DA32 Life Science Tech Acquisition Corp. Class A Common Stock shares in Q4 2022, an estimated $487K.
Soleus Capital Management first reported a position in DA32 Life Science Tech Acquisition Corp. Class A Common Stock in Q3 2021 and held it in 5 quarters.
Soleus Capital Management's DA32 Life Science Tech Acquisition Corp. Class A Common Stock position peaked at $3.44M in Q3 2021.
47 funds tracked by Wall St. Rank held DA32 Life Science Tech Acquisition Corp. Class A Common Stock as of Q4 2022.

Based on Soleus Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.